Company: OSRH
Filing Date: 2025-06-10
Form Type: S-1/A
Source: 0001213900-25-053114
Chunk: 50

Company: OSR Holdings, Inc.
Filing Date: 2025-06-10
Form: S-1/A
Chunk 50
---
543 |   |     |      |    540,207 |   |
| Cash and cash equivalents at end of year                                         |     | $                  |   1,595,697 |   |     | $    |    512,435 |   |
| Supplemental disclosures of cash flow information:                               |     |                    |             |   |     |      |            |   |
| Cash paid for interest                                                           |     | $                  |      16,991 |   |     | $    |     13,481 |   |
| Cash paid for income taxes (net of refunds received)                             |     |                    |         (35 | ) |     |      |      4,212 |   |

The accompanying notes are an integral part of the condensed consolidated financial statements. 33 OSR HOLDINGS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS March 31, 2025 and 2024 (UNAUDITED)

| (1) | Organization           
 and nature of business |

The condensed consolidated financial
statements of the Company and its subsidiaries (collectively, the “Group”) for the period ended March 31, 2025 were authorized
for issuance in accordance with a resolution of the directors meeting on May 7, 2025. The registered office is located at 37-36 Hoedong-gil,
Paju-si, Gyeongi-do, Republic of Korea.

The Company is a global life sciences
holding company based in South Korea and is actively engaging in drug development, dedicating to advance healthcare outcome and driving
social progress. Through open innovation and responsible investment, the Company aims to make a lasting impact across the industry as
well as our society. With a strong focus on oncology and immunology, the Company’s mission is to build a robust portfolio of ventures,
bringing innovative and transformative therapies to market.

Details of shareholders as of March 31, 2025 are as follows:

| Name of Shareholder                         |     | Number of      
 ordinary share |            |     | Percentage of 
 ownership     |        |   |
| Bellevue Global Life Sciences Investors LLC |     |                |  1,332,500 |     |               |   6.91 | % |
| Bellevue Capital Management Europe AG       |     |                |  8,612,634 |     |               |  44.68 | % |
| Bellevue Capital Management LLC             |     |                |